Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis.

Saini V, Ammerman NC, Chang YS, Tasneen R, Chaisson RE, Jain S, Nuermberger E, Grosset JH.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00388-19. doi: 10.1128/AAC.00388-19. Print 2019 Jun.

PMID:
30936097
2.

Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.

Almeida DV, Omansen TF, Li SY, Lee J, Grosset JH, Converse PJ, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02171-18. doi: 10.1128/AAC.02171-18. Print 2019 Mar.

PMID:
30559131
3.

High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.

Omansen TF, Almeida D, Converse PJ, Li SY, Lee J, Stienstra Y, van der Werf T, Grosset JH, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01478-18. doi: 10.1128/AAC.01478-18. Print 2019 Feb.

4.

Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.

Converse PJ, Almeida DV, Tasneen R, Saini V, Tyagi S, Ammerman NC, Li SY, Anders NM, Rudek MA, Grosset JH, Nuermberger EL.

PLoS Negl Trop Dis. 2018 Aug 13;12(8):e0006728. doi: 10.1371/journal.pntd.0006728. eCollection 2018 Aug.

5.

Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.

Ammerman NC, Swanson RV, Bautista EM, Almeida DV, Saini V, Omansen TF, Guo H, Chang YS, Li SY, Tapley A, Tasneen R, Tyagi S, Betoudji F, Moodley C, Ngcobo B, Pillay L, Bester LA, Singh SD, Chaisson RE, Nuermberger E, Grosset JH.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00636-18. doi: 10.1128/AAC.00636-18. Print 2018 Jul.

6.

Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo.

Ammerman NC, Swanson RV, Tapley A, Moodley C, Ngcobo B, Adamson J, Dorasamy A, Moodley S, Mgaga Z, Bester LA, Singh SD, Almeida DV, Grosset JH.

J Antimicrob Chemother. 2017 Feb;72(2):455-461. doi: 10.1093/jac/dkw417. Epub 2016 Oct 25.

PMID:
27798204
7.

Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy.

Swanson RV, Ammerman NC, Ngcobo B, Adamson J, Moodley C, Dorasamy A, Moodley S, Mgaga Z, Bester LA, Singh SD, Almeida DV, Grosset JH.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2864-9. doi: 10.1128/AAC.00177-16. Print 2016 May.

8.

Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins.

Kling A, Lukat P, Almeida DV, Bauer A, Fontaine E, Sordello S, Zaburannyi N, Herrmann J, Wenzel SC, König C, Ammerman NC, Barrio MB, Borchers K, Bordon-Pallier F, Brönstrup M, Courtemanche G, Gerlitz M, Geslin M, Hammann P, Heinz DW, Hoffmann H, Klieber S, Kohlmann M, Kurz M, Lair C, Matter H, Nuermberger E, Tyagi S, Fraisse L, Grosset JH, Lagrange S, Müller R.

Science. 2015 Jun 5;348(6239):1106-12. doi: 10.1126/science.aaa4690.

PMID:
26045430
9.

Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease.

Converse PJ, Tyagi S, Xing Y, Li SY, Kishi Y, Adamson J, Nuermberger EL, Grosset JH.

PLoS Negl Trop Dis. 2015 Jun 4;9(6):e0003823. doi: 10.1371/journal.pntd.0003823. eCollection 2015.

10.

Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis.

Swanson RV, Adamson J, Moodley C, Ngcobo B, Ammerman NC, Dorasamy A, Moodley S, Mgaga Z, Tapley A, Bester LA, Singh S, Grosset JH, Almeida DV.

Antimicrob Agents Chemother. 2015;59(6):3042-51. doi: 10.1128/AAC.00260-15. Epub 2015 Mar 9.

11.

Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations.

Andréjak C, Almeida DV, Tyagi S, Converse PJ, Ammerman NC, Grosset JH.

Antimicrob Agents Chemother. 2015 Apr;59(4):2129-35. doi: 10.1128/AAC.04841-14. Epub 2015 Jan 26.

12.

Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis.

Tyagi S, Ammerman NC, Li SY, Adamson J, Converse PJ, Swanson RV, Almeida DV, Grosset JH.

Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):869-74. doi: 10.1073/pnas.1416951112. Epub 2015 Jan 5.

13.

Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice.

Almeida DV, Tyagi S, Li S, Wallengren K, Pym AS, Ammerman NC, Bishai WR, Grosset JH.

Mycobact Dis. 2014 May 5;4:145.

14.

Accelerated detection of mycolactone production and response to antibiotic treatment in a mouse model of Mycobacterium ulcerans disease.

Converse PJ, Xing Y, Kim KH, Tyagi S, Li SY, Almeida DV, Nuermberger EL, Grosset JH, Kishi Y.

PLoS Negl Trop Dis. 2014 Jan 2;8(1):e2618. doi: 10.1371/journal.pntd.0002618. eCollection 2014.

15.

Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infection.

Zhang T, Li SY, Converse PJ, Grosset JH, Nuermberger EL.

PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2598. doi: 10.1371/journal.pntd.0002598. eCollection 2013.

16.

Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207).

Grosset JH, Ammerman NC.

Expert Rev Anti Infect Ther. 2013 Jul;11(7):649-51. doi: 10.1586/14787210.2013.811848.

PMID:
23879605
17.

Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.

Grosset JH, Tyagi S, Almeida DV, Converse PJ, Li SY, Ammerman NC, Bishai WR, Enarson D, Trébucq A.

Am J Respir Crit Care Med. 2013 Sep 1;188(5):608-12. doi: 10.1164/rccm.201304-0753OC.

18.

Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.

Ahmad Z, Tyagi S, Minkowski A, Peloquin CA, Grosset JH, Nuermberger EL.

Am J Respir Crit Care Med. 2013 Jul 1;188(1):97-102. doi: 10.1164/rccm.201212-2328OC.

19.

Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease.

Sarfo FS, Converse PJ, Almeida DV, Zhang J, Robinson C, Wansbrough-Jones M, Grosset JH.

PLoS Negl Trop Dis. 2013;7(3):e2101. doi: 10.1371/journal.pntd.0002101. Epub 2013 Mar 14.

20.

Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease.

Almeida DV, Converse PJ, Li SY, Tyagi S, Nuermberger EL, Grosset JH.

PLoS Negl Trop Dis. 2013;7(2):e2085. doi: 10.1371/journal.pntd.0002085. Epub 2013 Feb 28.

21.

Reply to "Contradictory results with high-dosage rifamycin in mice and humans".

Nuermberger EL, Rosenthal IM, Tasneen R, Peloquin CA, Mdluli KE, Karakousis PC, Grosset JH.

Antimicrob Agents Chemother. 2013 Feb;57(2):1104-5. doi: 10.1128/AAC.02216-12. No abstract available.

22.

Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.

Ahmad Z, Tyagi S, Minkowsk A, Almeida D, Nuermberger EL, Peck KM, Welch JT, Baughn AS, Jacobs WR Jr, Grosset JH.

Indian J Med Res. 2012 Nov;136(5):808-14.

23.

Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy.

Andréjak C, Almeida DV, Tyagi S, Converse PJ, Ammerman NC, Grosset JH.

J Antimicrob Chemother. 2013 Mar;68(3):659-65. doi: 10.1093/jac/dks421. Epub 2012 Nov 5.

24.

New drugs for the treatment of tuberculosis: hope and reality.

Grosset JH, Singer TG, Bishai WR.

Int J Tuberc Lung Dis. 2012 Aug;16(8):1005-14. doi: 10.5588/ijtld.12.0277. Review.

PMID:
22762423
25.

Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.

Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL.

Antimicrob Agents Chemother. 2012 Aug;56(8):4331-40. doi: 10.1128/AAC.00912-12. Epub 2012 Jun 4.

26.

Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.

Dutta NK, Illei PB, Peloquin CA, Pinn ML, Mdluli KE, Nuermberger EL, Grosset JH, Karakousis PC.

Antimicrob Agents Chemother. 2012 Jul;56(7):3726-31. doi: 10.1128/AAC.00500-12. Epub 2012 Apr 30.

27.

Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

Converse PJ, Nuermberger EL, Almeida DV, Grosset JH.

Future Microbiol. 2011 Oct;6(10):1185-98. doi: 10.2217/fmb.11.101. Review.

28.

Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models.

Ahmad Z, Fraig MM, Pinn ML, Tyagi S, Nuermberger EL, Grosset JH, Karakousis PC.

J Antimicrob Chemother. 2011 Jul;66(7):1560-6. doi: 10.1093/jac/dkr188. Epub 2011 May 20.

29.

BCG-mediated protection against Mycobacterium ulcerans infection in the mouse.

Converse PJ, Almeida DV, Nuermberger EL, Grosset JH.

PLoS Negl Trop Dis. 2011 Mar 15;5(3):e985. doi: 10.1371/journal.pntd.0000985.

30.

Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.

Zhang M, Li SY, Rosenthal IM, Almeida DV, Ahmad Z, Converse PJ, Peloquin CA, Nuermberger EL, Grosset JH.

Am J Respir Crit Care Med. 2011 May 1;183(9):1254-61. doi: 10.1164/rccm.201012-1949OC. Epub 2011 Feb 17.

31.

Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.

Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, Karakousis PC.

Antimicrob Agents Chemother. 2011 Apr;55(4):1527-32. doi: 10.1128/AAC.01524-10. Epub 2011 Jan 31.

32.

Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis.

Ahmad Z, Minkowski A, Peloquin CA, Williams KN, Mdluli KE, Grosset JH, Nuermberger EL.

Antimicrob Agents Chemother. 2011 Apr;55(4):1781-3. doi: 10.1128/AAC.01514-10. Epub 2011 Jan 31.

33.

Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.

Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, Grosset JH.

PLoS Negl Trop Dis. 2011 Jan 4;5(1):e933. doi: 10.1371/journal.pntd.0000933.

34.

Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.

Zhang T, Li SY, Converse PJ, Almeida DV, Grosset JH, Nuermberger EL.

Antimicrob Agents Chemother. 2011 Jan;55(1):56-61. doi: 10.1128/AAC.01260-10. Epub 2010 Nov 15.

35.

PA-824 exhibits time-dependent activity in a murine model of tuberculosis.

Ahmad Z, Peloquin CA, Singh RP, Derendorf H, Tyagi S, Ginsberg A, Grosset JH, Nuermberger EL.

Antimicrob Agents Chemother. 2011 Jan;55(1):239-45. doi: 10.1128/AAC.00849-10. Epub 2010 Oct 11.

36.

The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters.

Ahmad Z, Pinn ML, Nuermberger EL, Peloquin CA, Grosset JH, Karakousis PC.

J Antimicrob Chemother. 2010 Oct;65(10):2172-5. doi: 10.1093/jac/dkq277. Epub 2010 Aug 6.

37.

The impact of mouse passaging of Mycobacterium tuberculosis strains prior to virulence testing in the mouse and guinea pig aerosol models.

Converse PJ, Eisenach KD, Theus SA, Nuermberger EL, Tyagi S, Ly LH, Geiman DE, Guo H, Nolan ST, Akar NC, Klinkenberg LG, Gupta R, Lun S, Karakousis PC, Lamichhane G, McMurray DN, Grosset JH, Bishai WR.

PLoS One. 2010 Apr 21;5(4):e10289. doi: 10.1371/journal.pone.0010289.

38.

Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.

Zhang T, Bishai WR, Grosset JH, Nuermberger EL.

Antimicrob Agents Chemother. 2010 Jul;54(7):2806-13. doi: 10.1128/AAC.00400-10. Epub 2010 Apr 26.

39.

Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.

Ahmad Z, Nuermberger EL, Tasneen R, Pinn ML, Williams KN, Peloquin CA, Grosset JH, Karakousis PC.

J Antimicrob Chemother. 2010 Apr;65(4):729-34. doi: 10.1093/jac/dkq007. Epub 2010 Jan 31.

40.

Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.

Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL.

Am J Respir Crit Care Med. 2009 Dec 1;180(11):1151-7. doi: 10.1164/rccm.200905-0795OC. Epub 2009 Sep 3.

41.

Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.

Ahmad Z, Klinkenberg LG, Pinn ML, Fraig MM, Peloquin CA, Bishai WR, Nuermberger EL, Grosset JH, Karakousis PC.

J Infect Dis. 2009 Oct 1;200(7):1136-43. doi: 10.1086/605605.

PMID:
19686043
42.

Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.

Williams KN, Brickner SJ, Stover CK, Zhu T, Ogden A, Tasneen R, Tyagi S, Grosset JH, Nuermberger EL.

Am J Respir Crit Care Med. 2009 Aug 15;180(4):371-6. doi: 10.1164/rccm.200904-0611OC. Epub 2009 Jun 11.

PMID:
19520903
43.

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE; Tuberculosis Trials Consortium.

Am J Respir Crit Care Med. 2009 Aug 1;180(3):273-80. doi: 10.1164/rccm.200901-0078OC. Epub 2009 Apr 30.

PMID:
19406981
44.

Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models.

Converse PJ, Karakousis PC, Klinkenberg LG, Kesavan AK, Ly LH, Allen SS, Grosset JH, Jain SK, Lamichhane G, Manabe YC, McMurray DN, Nuermberger EL, Bishai WR.

Infect Immun. 2009 Mar;77(3):1230-7. doi: 10.1128/IAI.01117-08. Epub 2008 Dec 22.

45.

Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.

Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E.

Antimicrob Agents Chemother. 2009 Apr;53(4):1314-9. doi: 10.1128/AAC.01182-08. Epub 2008 Dec 15.

46.

Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?

Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL.

Am J Respir Crit Care Med. 2008 Nov 1;178(9):989-93. doi: 10.1164/rccm.200807-1029OC. Epub 2008 Aug 21.

47.

Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.

Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D, Rosenthal I, Grosset JH.

Antimicrob Agents Chemother. 2008 Apr;52(4):1522-4. doi: 10.1128/AAC.00074-08. Epub 2008 Feb 19.

48.

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.

Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL.

PLoS Med. 2007 Dec;4(12):e344.

49.

Evaluation of new antituberculosis drugs in mouse models.

Davies GR, Pym AS, Mitchison DA, Nuermberger EL, Grosset JH.

Antimicrob Agents Chemother. 2007 Jan;51(1):403; author reply 403-4. No abstract available.

50.

Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.

Nuermberger E, Rosenthal I, Tyagi S, Williams KN, Almeida D, Peloquin CA, Bishai WR, Grosset JH.

Antimicrob Agents Chemother. 2006 Aug;50(8):2621-5.

Supplemental Content

Loading ...
Support Center